Eurogin Roadmap: Comparative epidemiology of HPV infection and associated cancers of the head and neck and cervix

International Journal of Cancer

Volumn 134, Issue 3, 2014, Pages 497-507

  Gillison, Maura L ^a   Castellsagué, Xavier ^b   Chaturvedi, Anil ^c   Goodman, Marc T ^d   Snijders, Peter ^e   Tommasino, Massimo ^f   Arbyn, Marc ^g,h   Franceschi, Silvia ^f  

^a OHIO STATE UNIVERSITY   (United States)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c NATIONAL CANCER INSTITUTE   (United States)

^d CEDARS SINAI MEDICAL CENTER   (United States)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^g SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

^h UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

cervical cancer; epidemiology; head and neck cancer; human papillomavirus

Indexed keywords

MESSENGER RNA; VIRUS DNA; WART VIRUS VACCINE;

CANCER GRADING; CANCER PROGNOSIS; CANCER SURVIVAL; CHROMOSOME ABERRATION; DISEASE ACTIVITY; DISEASE ASSOCIATION; DNA METHYLATION; DRUG APPROVAL; DRUG EFFICACY; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION; GEOGRAPHIC DISTRIBUTION; HEAD AND NECK CANCER; HUMAN; INFECTION RISK; MOLECULAR PATHOLOGY; NONHUMAN; OROPHARYNX CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAPILLOMAVIRUS INFECTION; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SECONDARY PREVENTION; SURVIVAL RATE; UTERINE CERVIX CANCER; VIRUS IDENTIFICATION; WART VIRUS;

EID: 84887995124     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28201     Document Type: Review

References (108)

1. Durst M, Gissmann L, Ikenberg H, et al. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci USA 1983; 80: 3812-15.
2. IARC. IARC monograph on the evaluation of carcinogenic risks to humans. Lyon, France: IARC, 1995.
3. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-19.
4. IARC monographs on the evaluation of carcinogenic risks to humans. In: Cancer IAfRo, ed. Lyon, France: World Health Organization, 2007. 670.
5. WHO. A review of human carcinogens. Biological agents. Lyon: World Health Organization, 2012.
6. Trottier H, Franco EL,. The epidemiology of genital human papillomavirus infection. Vaccine 2006; 24 (Suppl 1): S1-S15.
7. Gillison M, Broutian T, Pickard R, et al. Prevalence of oral HPV infection in the United States, 2009-2010. JAMA 2012; 307: 693-703.
8. Dunne EF, Unger ER, Sternberg M, et al. Prevalence of HPV infection among females in the United States. JAMA 2007; 297: 813-19.
9. Harari S, Unger E, Sternberg M, et al. Prevalence of genital human papillomavirus among females in the United Stated, the national health and nutrition examination survey, 2003-2006. J Infect Dis 2011; 204: 566-73.
10. Burchell AN, Winer RL, de Sanjose S, et al. Epidemiology and transmission dynamics of genital HPV infection. Vaccine 2006; 24 (Suppl 3): S3/52-61.
11. Moscicki AB, Schiffman M, Burchell A, et al. Updating the natural history of human papillomavirus and anogenital cancers. Vaccine 2012; 30 (Suppl 5): F24-F33.
12. Pickard R, Xiao W, Broutian T, et al. The prevalence and incidence of oral human papillomavirus infection among young men and women, age 18-30 years. Sex Transm Dis 2012; 39: 559-66.
13. D'Souza G, Fakhry C, Sugar EA, et al. Six-month natural history of oral versus cervical human papillomavirus infection. Int J Cancer 2007; 121: 143-50.
14. Fakhry C, Sugar E, Pevtsova C, et al. Two-week versus six-month sampling interval in a short-term natural history study of oral HPV infection in an HIV-positive cohort. PLOS one 2010; 5: e11918.
15. D'souza G, Agrawal Y, Halpern J, et al. Oral sexual behaviors associated with prevalent oral human papillomavirus infection. J Infect Dis 2009; 199: 1263-9.
16. Gravitt PE,. The known unknowns of HPV natural history. J Clin Invest 2011; 121: 4593-9.
17. Bruni L, Diaz M, Castellsague X, et al. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 2010; 202: 1789-99.
18. Kreimer AR, Villa A, Nyitray AG, et al. The epidemiology of oral HPV infection among a multinational sample of healthy men. Cancer Epidemiol Biomarkers Prev 2011; 20: 172-82.
19. Kreimer A, Bhatia R, Messeguer A, et al. Oral human papillomavirus in healthy individuals: a systematic review of the literature. Sex Transm Dis 2010; 37: 386-91.
20. Giuliano AR, Lee JH, Fulp W, et al. Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study. Lancet 2011; 377: 932-40.
21. De Martel C, Ferlay J, Franceschi S, et al. The global burden of cancers attributable to infections in the year 2008: a review and synthetic analysis. Lancet Oncol 2012; 13: 607-15.
22. Arbyn M, de Sanjose S, Saraiya M, et al. EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease. Int J Cancer 2012; 131: 1969-82.
23. Ferlay J, Shin HR, Bray F, Forman D, Mathus C, Parkin OM,. Glubocan 2008v2.0. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. Lyon, France: International Agency for Research on Cancer, 2010 from: http://glubocan.iarc.fr. Last Accessed on: November 13, 2012.
24. Chaturvedi AK, Madeleine MM, Biggar RJ, et al. Risk of human papillomavirus-associated cancers among persons with AIDS. J Natl Cancer Inst 2009; 101: 1120-30.
25. Mehanna H, Beech T, Nicholson T, et al. The prevalence of human papillomavirus in oropharyngeal and non-oropharyngeal head and neck cancer-a systematic review and meta-analysis of trends by time and region. Head Neck 2013; 35: 747-55.
26. Kreimer AR, Clifford GM, Boyle P, et al. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005; 14: 467-75.
27. de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010; 11: 1048-56.
28. Li N, Franceschi S, Howell-Jones R, et al. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int J Cancer 2010; 128: 927-35.
29. St Guily JL, Jacquard AC, Pretet JL, et al. Human papillomavirus genotype distribution in oropharynx and oral cavity cancer in France-the EDiTH VI study. J Clin Virol 2011; 51: 100-4.
30. Chaturvedi A, Engels E, Pfeiffer R, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011; 29: 4294-301.
31. WHO. Tobacco smoke and involutary smoking. In: IARC monographs on the evaluation of carcinogenic risks to humans. Lyon: WHO Press, 2004.
32. Appleby P, Beral V, Berrington de Gonzalez A, et al. Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies. Int J Cancer 2006; 118: 1481-95.
33. Gillison M, D'souza G, Westra W, et al. Distinct risk factor profiles for human papillomaviurs type 16-positive and human papillomavirus 16-negative head and neck cancers. J Natl Cancer Inst 2008; 100: 407-20.
34. D'Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007; 356: 1944-56.
35. Herrero R, Castellsague X, Pawlita M, et al. Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst 2003; 95: 1772-83.
36. Ribeiro K, Levi J, Pawlita M, et al. Low human papillomavirus prevalence in head and neck cancer: results from two large case-control studies in high-incidence regions. Int J Epidemiol 2011; 40: 489-502.
37. Gillison ML,. Current topics in the epidemiology of oral cavity and oropharyngeal cancers. Head Neck 2007; 29: 779-92.
38. Guha N, Boffetta P, Wunsch Filho V, et al. Oral health and risk of squamous cell carcinoma of the head and neck and esophagus: results of two multicentric case-control studies. Am J Epidemiol 2007; 166: 1159-73.
39. Franceschi S, Rajkumar T, Vaccarella S, et al. Human papillomavirus and risk factors for cervical cancer in Chennai, India: a case-control study. Int J Cancer 2003; 107: 127-33.
40. Parikh S, Brennan P, Boffetta P,. Meta-analysis of social inequality and the risk of cervical cancer. Int J Cancer 2003; 105: 687-91.
41. Benard VB, Johnson CJ, Thompson TD, et al. Examining the association between socioeconomic status and potential human papillomavirus-associated cancers. Cancer 2008; 113: 2910-18.
42. Tezal M,. Interaction between chronic inflammation and oral HPV infection in the etiology of head and neck cancers. Int J Otolaryngol 2012; 2012: 575242.
43. Ahn J, Segers S, Hayes RB,. Periodontal disease, Porphyromonas gingivalis serum antibody levels and orodigestive cancer mortality. Carcinogenesis 2012; 33: 1055-8.
44. Meyer MS, Joshipura K, Giovannucci E, et al. A review of the relationship between tooth loss, periodontal disease, and cancer. Cancer Causes Control 2008; 19: 895-907.
45. Tezal M, Sullivan MA, Hyland A, et al. Chronic periodontitis and the incidence of head and neck squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 2009; 18: 2406-12.
46. Gillet E, Meys JF, Verstraelen H, et al. Association between bacterial vaginosis and cervical intraepithelial neoplasia: systematic review and meta-analysis. PLOS one 2012; 7: e45201.
47. Smith JS, Herrero R, Bosetti C, et al. Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. J Natl Cancer Inst 2002; 94: 1604-13.
48. Smith JS, Bosetti C, Munoz N, et al. Chlamydia trachomatis and invasive cervical cancer: a pooled analysis of the IARC multicentric case-control study. Int J Cancer 2004; 111: 431-9.
49. Naucler P, Chen HC, Persson K, et al. Seroprevalence of human papillomaviruses and Chlamydia trachomatis and cervical cancer risk: nested case-control study. J Gen Virol 2007; 88: 814-22.
50. Safaeian M, Quint K, Schiffman M, et al. Chlamydia trachomatis and risk of prevalent and incident cervical premalignancy in a population-based cohort. J Natl Cancer Inst 2010; 102: 1794-804.
51. Cervical carcinoma and reproductive factors: collaborative reanalysis of individual data on 16,563 women with cervical carcinoma and 33,542 women without cervical carcinoma from 25 epidemiological studies. Int J Cancer 2006; 119: 1108-24.
52. Cervical carcinoma and sexual behavior: collaborative reanalysis of individual data on 15,461 women with cervical carcinoma and 29,164 women without cervical carcinoma from 21 epidemiological studies. Cancer Epidemiol Biomarkers Prev 2009; 18: 1060-9.
53. Appleby P, Beral V, Berrington de Gonzalez A, et al. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet 2007; 370: 1609-21.
54. Plummer M, Peto J, Franceschi S,. Time since first sexual intercourse and the risk of cervical cancer. Int J Cancer 2012; 130: 2638-44.
55. Rinaldi S, Plummer M, Biessy C, et al. Endogenous sex steroids and risk of cervical carcinoma: results from the EPIC study. Cancer Epidemiol Biomarkers Prev 2011; 20: 2532-40.
56. Allen E, Gardner W,. Cancer of the cervix of the uterus in hybrid mice following long-continues administration of estrogen. Cancer Res 1941; 1: 359-66.
57. Chung SH, Franceschi S, Lambert PF,. Estrogen and ERalpha: culprits in cervical cancer? Trends Endocrinol Metab 2010; 21: 504-11.
58. Hwang LY, Ma Y, Benningfield SM, et al. Factors that influence the rate of epithelial maturation in the cervix in healthy young women. J Adolesc Health 2009; 44: 103-10.
59. McLaughlin-Drubin ME, Crum CP, Munger K,. Human papillomavirus E7 oncoprotein induces KDM6A and KDM6B histone demethylase expression and causes epigenetic reprogramming. Proc Natl Acad Sci USA 2011; 108: 2130-5.
60. Wentzensen N, von Knebel Doeberitz M,. Biomarkers in cervical cancer screening. Dis Markers 2007; 23: 315-30.
61. Smeets SJ, Brakenhoff RH, Ylstra B, et al. Genetic classification of oral and oropharyngeal carcinomas identifies subgroups with a different prognosis. Cell Oncol 2009; 31: 291-300.
62. Hoffmann M, Ihloff AS, Gorogh T, et al. p16(INK4a) overexpression predicts translational active human papillomavirus infection in tonsillar cancer. Int J Cancer 2010; 127: 1595-602.
63. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000; 92: 709-20.
64. Braakhuis BJ, Snijders PJ, Keune WJ, et al. Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus. J Natl Cancer Inst 2004; 96: 998-1006.
65. Dai M, Clifford GM, le Calvez F, et al. Human papillomavirus type 16 and TP53 mutation in oral cancer: matched analysis of the IARC multicenter study. Cancer Res 2004; 64: 468-71.
66. Westra W, Taube J, Poeta M, et al. Inverse relationship between human papillomavirus-16 infection and disruptive p53 gene mutations in squamous cell carcinoma of the head and neck. Clin Cancer Res 2008; 14: 366-9.
67. Strati K, Pitot HC, Lambert PF,. Identification of biomarkers that distinguish human papillomavirus (HPV)-positive versus HPV-negative head and neck cancers in a mouse model. Proc Natl Acad Sci USA 2006; 103: 14152-7.
68. Jabbar S, Strati K, Shin MK, et al. Human papillomavirus type 16 E6 and E7 oncoproteins act synergistically to cause head and neck cancer in mice. Virology 2010; 407: 60-7.
69. Smeets S, Braakhuis B, Abbas S, et al. Genome-wide DNA copy number alterations in head and neck squamous cell carcinomas with or without oncogene-expressing human papillomavirus. Oncogene 2006; 25: 2558-64.
70. Niedobitek G, Pitteroff S, Herbst H, et al. Detection of human papillomavirus type 16 DNA in carcinomas of the palatine tonsil. J Clin Pathol 1990; 43: 918-21.
71. Begum S, Cao D, Gillison M, et al. Tissue distribution of human papillomavirus 16 DNA integration in patients with tonsillar carcinoma. Clin Cancer Res 2005; 11: 5694-9.
72. Lace MJ, Anson JR, Klussmann JP, et al. Human papillomavirus type 16 (HPV-16) genomes integrated in head and neck cancers and in HPV-16-immortalized human keratinocyte clones express chimeric virus-cell mRNAs similar to those found in cervical cancers. J Virol 2011; 85: 1645-54.
73. Butz K, Ristriani T, Hengstermann A, et al. siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells. Oncogene 2003; 22: 5938-45.
74. Horner SM, DeFilippis RA, Manuelidis L, et al. Repression of the human papillomavirus E6 gene initiates p53-dependent, telomerase-independent senescence and apoptosis in HeLa cervical carcinoma cells. J Virol 2004; 78: 4063-73.
75. Rampias T, Sasaki C, Weinberger P, et al. E6 and E7 gene silencing and transformed phenotype of human papillomavirus 16-positive oropharyngeal cancer cells. J Natl Cancer Inst 2009; 101: 412-23.
76. Wilting SM, Smeets SJ, Snijders PJ, et al. Genomic profiling identifies common HPV-associated chromosomal alterations in squamous cell carcinomas of cervix and head and neck. BMC Med Genomics 2009; 2: 32.
77. Pyeon D, Newton MA, Lambert PF, et al. Fundamental differences in cell cycle deregulation in human papillomavirus-positive and human papillomavirus-negative head/neck and cervical cancers. Cancer Res 2007; 67: 4605-19.
78. Sartor MA, Dolinoy DC, Jones TR, et al. Genome-wide methylation and expression differences in HPV(+) and HPV(-) squamous cell carcinoma cell lines are consistent with divergent mechanisms of carcinogenesis. Epigenetics 2011; 6: 777-87.
79. Lajer CB, Garnaes E, Friis-Hansen L, et al. The role of miRNAs in human papilloma virus (HPV)-associated cancers: bridging between HPV-related head and neck cancer and cervical cancer. Br J Cancer 2012; 106: 1526-34.
80. Lavaf A, Genden EM, Cesaretti JA, et al. Adjuvant radiotherapy improves overall survival for patients with lymph node-positive head and neck squamous cell carcinoma. Cancer 2008; 112: 535-43.
81. Rogers L, Siu SS, Luesley D, et al. Radiotherapy and chemoradiation after surgery for early cervical cancer. Cochrane Database Syst Rev 2012; 5: CD007583.
82. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004; 350: 1937-44.
83. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004; 350: 1945-52.
84. Peters WA, III, Liu PY, Barrett RJ, II, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000; 18: 1606-13.
85. Bansal N, Herzog TJ, Shaw RE, et al. Primary therapy for early-stage cervical cancer: radical hysterectomy vs. radiation. Am J Obstet Gynecol 2009; 201: 485 e1-9.
86. Posner M, Hershock D, Blajman C, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007; 358: 1705-15.
87. Pignon J-P, le Maitre A, Maillard E, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009; 92: 4-14.
88. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data meta-analysis. Cochrane Database Syst Rev 2010; 1: CD008285.
89. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-78.
90. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359: 1116-27.
91. Kenter GG, Welters MJ, Valentijn AR, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009; 361: 1838-47.
92. Howlader N, Noone AM, Krapchu M, Gershell J, Nexman N, AlteKruse SF, Kosary CL, Yu M, Ruhl J, Tatalovid Z, Cho H, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA, (eds). SEER Cancer Statistics Review, 1975-2010, National Cancer Institute, Bethesda, MD, http://seer.cancer.gov/cpr/1975-2c.
93. Ang K, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363: 24-35.
94. Jung A, Briolat J, Millon R, et al. Biological and clinical relevance of transcriptionally active human papillomavirus (HPV) in oropharynx squamous cell carcinoma. Int J Cancer 2010; 126: 1882-94.
95. Jordan R, Lingen M, Perez-Ordonez B, et al. Validation of methods for oropharyngeal cancer HPV sttus determination in US cooperative group trials. Am J Surg Pathol 2012; 36: 945-54.
96. Schlecht N, Brandwein-Gensler M, Nuovo G, et al. A comparison of clinically utilized human papillomavirus detection methods in head and neck cancer. Mod Pathol 2011; 24: 1295-305.
97. Smeets SJ, Hesselink AT, Speel EJ, et al. A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer 2007; 121: 2465-72.
98. Peto J, Gilham C, Fletcher O, et al. The cervical cancer epidemic that screening has prevented in the UK. Lancet 2004; 364: 249-56.
99. Andrae B, Andersson TM, Lambert PC, et al. Screening and cervical cancer cure: population based cohort study. BMJ 2012; 344: e900.
100. Sankaranarayanan R, Ramadas K, Thomas G, et al. Effect of screening on oral cancer mortality in Kerala, India: a cluster-randomised controlled trial. Lancet 2005; 365: 1927-33.
101. Fakhry C, Rosenthal BT, Clark DP, et al. Associations between oral HPV16 infection and cytopathology: evaluation of an oropharyngeal "pap-test equivalent" in high-risk populations. Cancer Prev Res (Phila) 2011; 4: 1378-84.
102. Begum S, Gillison ML, Nicol TL, et al. Detection of human papillomavirus-16 in fine-needle aspirates to determine tumor origin in patients with metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res 2007; 13: 1186-91.
103. Koshiol J, Lindsay L, Pimenta JM, et al. Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol 2008; 168: 123-37.
104. Schiffman M, Glass AG, Wentzensen N, et al. A long-term prospective study of type-specific human papillomavirus infection and risk of cervical neoplasia among 20,000 women in the Portland Kaiser Cohort Study. Cancer Epidemiol Biomarkers Prev 2011; 20: 1398-409.
105. Sankaranarayanan R, Nene BM, Shastri SS, et al. HPV screening for cervical cancer in rural India. N Engl J Med 2009; 360: 1385-94.
106. Arbyn M, Ronco G, Anttila A, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 2012; 30 (Suppl 5): F88-F99.
107. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356: 1928-43.
108. Lehtinen M, Paavonen J, Wheeler CM, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012; 13: 89-99.